{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T18:50:35Z","timestamp":1775069435241,"version":"3.50.1"},"reference-count":46,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T00:00:00Z","timestamp":1629849600000},"content-version":"unspecified","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,6,7]]},"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>This phase I dose escalation trial evaluated the feasibility of production, safety, maximum tolerated dose, and preliminary efficacy of autologous T cells sensitized with peptides encoding Wilms\u2019 tumor protein 1 (WT1) administered alone or following lymphodepleting chemotherapy, in the treatment of patients with recurrent WT1<jats:sup>+<\/jats:sup> ovarian, primary peritoneal, or fallopian tube carcinomas.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A 3+3 dose escalation design was used to determine dose-limiting toxicity (DLT). In cohort I, patients received WT1-sensitized T cells dosed at 5\u00d710<jats:sup>6<\/jats:sup>\/m<jats:sup>2<\/jats:sup> (level I) without cyclophosphamide lymphodepletion. In cohorts II\u2013IV, patients received lymphodepleting chemotherapy (a single intravenous dose of cyclophosphamide 750 mg\/m<jats:sup>2<\/jats:sup>), 2 days prior to the first intravenous infusion of WT1-sensitized T cells administered at escalating doses (2\u00d710<jats:sup>7<\/jats:sup>\/m<jats:sup>2<\/jats:sup> (level II), 5\u00d710<jats:sup>7<\/jats:sup>\/m<jats:sup>2<\/jats:sup> (level III), and 1\u00d710<jats:sup>8<\/jats:sup>\/m<jats:sup>2<\/jats:sup> (level IV)).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Twelve patients aged 23\u201372 years, with a median of 7 prior therapies (range 4\u201314), were treated on the study. No DLT was observed, even at the highest dose level of 1\u00d710<jats:sup>8<\/jats:sup>\/m<jats:sup>2<\/jats:sup> WT1-sensitized T cells tested. Common adverse events reported were grade 1\u20132 fatigue, fever, nausea, and headache. Median progression-free survival (PFS) was 1.8 months (95% CI, 0.8 to 2.6); 1 year PFS rate 8.3% (95% CI, 0.5 to 31.1). Median overall survival (OS) was 11.0 months (95% CI, 1.1 to 22.6); OS at 1 year was 41.7% (95% CI, 15.2% to 66.5%). Best response was stable disease in one patient (n=1) and progressive disease in the others (n=11). We observed a transient increase in the frequencies of WT1-specific cytotoxic T lymphocyte precursors (CTLp) in the peripheral blood of 9 of the 12 patients following WT1-sensitized T-cell infusion.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>We demonstrated the safety of administration of WT1-sensitized T cells and the short-term increase in the WT1 CTLp. However, at the low doses evaluated we did not observe therapeutic activity in recurrent ovarian cancer. In this heavily pretreated population, we encountered challenges in generating sufficient numbers of WT1-reactive cytotoxic T cells. Future studies employing WT1-specific T cells generated from lymphocytes are warranted but should be done earlier in the disease course and prior to intensive myelosuppressive therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00562640\">NCT00562640<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>One-sentence summary<\/jats:title>\n                  <jats:p>The authors describe the first human application of autologous WT1-sensitized T cells in the treatment of patients with recurrent ovarian, primary peritoneal, and fallopian tube carcinomas.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2021-002752","type":"journal-article","created":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T13:00:28Z","timestamp":1629896428000},"page":"e002752","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct00562640","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02550535","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02408016","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00562640","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Chrisann","family":"Kyi","sequence":"first","affiliation":[{"name":"Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"},{"name":"Medicine, Weill Cornell Medical College, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina","family":"Doubrovina","sequence":"additional","affiliation":[{"name":"Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Epidemiology-Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Kravetz","sequence":"additional","affiliation":[{"name":"Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexia","family":"Iasonos","sequence":"additional","affiliation":[{"name":"Epidemiology-Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Aghajanian","sequence":"additional","affiliation":[{"name":"Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"},{"name":"Medicine, Weill Cornell Medical College, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Sabbatini","sequence":"additional","affiliation":[{"name":"Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"},{"name":"Medicine, Weill Cornell Medical College, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Spriggs","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J","family":"O'Reilly","sequence":"additional","affiliation":[{"name":"Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8217-4554","authenticated-orcid":false,"given":"Roisin E","family":"O\u2019Cearbhaill","sequence":"additional","affiliation":[{"name":"Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA"},{"name":"Medicine, Weill Cornell Medical College, New York, New York, USA"},{"name":"National University of Ireland, Galway, Galway, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,8,25]]},"reference":[{"key":"2025100300525009000_9.8.e002752.1","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"2025100300525009000_9.8.e002752.2","unstructured":"Hoskins WJ , Perez CA , Young RC . Principles and practice of gynecologic oncology. In: . 3. Philadelphia: Lippincott Williams & Wilkins, 2000: 1268."},{"key":"2025100300525009000_9.8.e002752.3","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1200\/JCO.2014.55.1713","article-title":"Prognosis and conditional disease-free survival among patients with ovarian cancer","volume":"32","author":"Kurta","year":"2014","journal-title":"J Clin Oncol"},{"key":"2025100300525009000_9.8.e002752.4","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ygyno.2015.12.030","article-title":"Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine","volume":"141","author":"Zamarin","year":"2016","journal-title":"Gynecol Oncol"},{"key":"2025100300525009000_9.8.e002752.5","first-page":"62","article-title":"Adoptive T cell immunotherapy strategies for the treatment of patients with ovarian cancer","volume":"9","author":"Chekmasova","year":"2010","journal-title":"Discov Med"},{"key":"2025100300525009000_9.8.e002752.6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N Engl J Med"},{"key":"2025100300525009000_9.8.e002752.7","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1046\/j.1365-2796.2001.00911.x","article-title":"Progress in the development of immunotherapy for the treatment of patients with cancer","volume":"250","author":"Rosenberg","year":"2001","journal-title":"J Intern Med"},{"key":"2025100300525009000_9.8.e002752.8","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/sj.leu.2403817","article-title":"Wilms' tumour gene 1 (WT1) in human neoplasia","volume":"19","author":"Keilholz","year":"2005","journal-title":"Leukemia"},{"key":"2025100300525009000_9.8.e002752.9","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1242\/dev.119.4.1329","article-title":"Nuclear localization of the protein encoded by the Wilms' tumor gene WT1 in embryonic and adult tissues","volume":"119","author":"Mundlos","year":"1993","journal-title":"Development"},{"key":"2025100300525009000_9.8.e002752.10","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1182\/blood.V88.6.2267.bloodjournal8862267","article-title":"Long-Term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels","volume":"88","author":"Inoue","year":"1996","journal-title":"Blood"},{"key":"2025100300525009000_9.8.e002752.11","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood.V84.9.3071.3071","article-title":"Wt1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia","volume":"84","author":"Inoue","year":"1994","journal-title":"Blood"},{"key":"2025100300525009000_9.8.e002752.12","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/sj.leu.2400620","article-title":"Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia","volume":"11","author":"Schmid","year":"1997","journal-title":"Leukemia"},{"key":"2025100300525009000_9.8.e002752.13","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1200\/JCO.2003.10.503","article-title":"Significant correlation between the degree of WT1 expression and the International prognostic scoring system score in patients with myelodysplastic syndromes","volume":"21","author":"Cilloni","year":"2003","journal-title":"J Clin Oncol"},{"key":"2025100300525009000_9.8.e002752.14","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood.V95.1.286","article-title":"HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide","volume":"95","author":"Ohminami","year":"2000","journal-title":"Blood"},{"key":"2025100300525009000_9.8.e002752.15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s002510050018","article-title":"Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product","volume":"51","author":"Oka","year":"2000","journal-title":"Immunogenetics"},{"key":"2025100300525009000_9.8.e002752.16","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1182\/blood.V95.7.2198","article-title":"Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1","volume":"95","author":"Gao","year":"2000","journal-title":"Blood"},{"key":"2025100300525009000_9.8.e002752.17","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJM198310133091503","article-title":"A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer","volume":"309","author":"Bast","year":"1983","journal-title":"N Engl J Med"},{"key":"2025100300525009000_9.8.e002752.18","first-page":"4779","article-title":"Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy","volume":"29","author":"Ohno","year":"2009","journal-title":"Anticancer Res"},{"key":"2025100300525009000_9.8.e002752.19","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.smim.2010.02.003","article-title":"Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation","volume":"22","author":"O'Reilly","year":"2010","journal-title":"Semin Immunol"},{"key":"2025100300525009000_9.8.e002752.20","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1038\/sj.leu.2404380","article-title":"Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein","volume":"20","author":"Pinilla-Ibarz","year":"2006","journal-title":"Leukemia"},{"key":"2025100300525009000_9.8.e002752.21","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ijc.1282","article-title":"Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues","volume":"92","author":"Jungbluth","year":"2001","journal-title":"Int J Cancer"},{"key":"2025100300525009000_9.8.e002752.22","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1182\/blood-2002-01-0163","article-title":"Cd8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia","volume":"100","author":"Scheibenbogen","year":"2002","journal-title":"Blood"},{"key":"2025100300525009000_9.8.e002752.23","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood-2011-11-394619","article-title":"Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias","volume":"120","author":"Doubrovina","year":"2012","journal-title":"Blood"},{"key":"2025100300525009000_9.8.e002752.24","doi-asserted-by":"crossref","first-page":"7483","DOI":"10.1158\/1078-0432.CCR-17-2169","article-title":"A randomized phase II trial of adjuvant Galinpepimut-S, WT-1 analogue peptide vaccine, after multimodality therapy for patients with malignant pleural mesothelioma","volume":"23","author":"Zauderer","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2025100300525009000_9.8.e002752.25","doi-asserted-by":"crossref","first-page":"5553","DOI":"10.1200\/JCO.2018.36.15_suppl.5553","article-title":"A phase I study of concomitant galinpepimut-s (GPs) in combination with nivolumab (nivo) in patients (PTS) with WT1+ ovarian cancer (OC) in second or third remission","volume":"36","author":"O'Cearbhaill","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"2025100300525009000_9.8.e002752.26","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1600-065X.1997.tb00983.x","article-title":"Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts","volume":"157","author":"O'Reilly","year":"1997","journal-title":"Immunol Rev"},{"key":"2025100300525009000_9.8.e002752.27","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1158\/1078-0432.CCR-14-2208","article-title":"Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans","volume":"21","author":"Chandran","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2025100300525009000_9.8.e002752.28","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2025100300525009000_9.8.e002752.29","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1200\/JCO.2006.07.1100","article-title":"Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma","volume":"24","author":"Mackensen","year":"2006","journal-title":"J Clin Oncol"},{"key":"2025100300525009000_9.8.e002752.30","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ygyno.2004.05.014","article-title":"Wilms tumor gene (WT1) and p53 expression in endometrial carcinomas: a study of 130 cases using a tissue microarray","volume":"94","author":"Dupont","year":"2004","journal-title":"Gynecol Oncol"},{"key":"2025100300525009000_9.8.e002752.31","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.1158\/1078-0432.CCR-04-1040","article-title":"In vitro stimulation with WT1 peptide-loaded Epstein-Barr virus-positive B cells elicits high frequencies of WT1 peptide-specific T cells with in vitro and in vivo tumoricidal activity","volume":"10","author":"Doubrovina","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2025100300525009000_9.8.e002752.32","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood.V87.6.2594.bloodjournal8762594","article-title":"The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation","volume":"87","author":"Lucas","year":"1996","journal-title":"Blood"},{"key":"2025100300525009000_9.8.e002752.33","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2025100300525009000_9.8.e002752.34","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and Ca 125 agreed by the gynecological cancer intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"2025100300525009000_9.8.e002752.35","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","article-title":"Efficacy and safety of Avelumab for patients with recurrent or refractory ovarian cancer: phase 1B results from the javelin solid tumor trial","volume":"5","author":"Disis","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100300525009000_9.8.e002752.36","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1093\/annonc\/mds203","article-title":"The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane\/platinum-based therapy","volume":"23","author":"Hanker","year":"2012","journal-title":"Ann Oncol"},{"key":"2025100300525009000_9.8.e002752.37","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41591-019-0472-9","article-title":"T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant","volume":"25","author":"Chapuis","year":"2019","journal-title":"Nat Med"},{"key":"2025100300525009000_9.8.e002752.38","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/EDBK_180328","article-title":"Adoptive T-cell therapy for solid tumors","volume":"37","author":"Yeku","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025100300525009000_9.8.e002752.39","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/PPO.0000000000000516","article-title":"How do we meet the challenge of chimeric antigen receptor T-cell therapy for solid tumors?","volume":"27","author":"Schoenfeld","year":"2021","journal-title":"Cancer J"},{"key":"2025100300525009000_9.8.e002752.40","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1158\/0008-5472.CAN-06-4047","article-title":"Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer","volume":"67","author":"Barber","year":"2007","journal-title":"Cancer Res"},{"key":"2025100300525009000_9.8.e002752.41","doi-asserted-by":"crossref","DOI":"10.4161\/2162402X.2014.994446","article-title":"IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo","volume":"4","author":"Koneru","year":"2015","journal-title":"Oncoimmunology"},{"key":"2025100300525009000_9.8.e002752.42","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025100300525009000_9.8.e002752.43","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1080\/14712598.2016.1176138","article-title":"Opportunities and challenges for TCR mimic antibodies in cancer therapy","volume":"16","author":"Chang","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"2025100300525009000_9.8.e002752.44","doi-asserted-by":"crossref","DOI":"10.4161\/onci.24678","article-title":"Approaching untargetable tumor-associated antigens with antibodies","volume":"2","author":"Dao","year":"2013","journal-title":"Oncoimmunology"},{"key":"2025100300525009000_9.8.e002752.45","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005661","article-title":"Targeting the intracellular WT1 oncogene product with a therapeutic human antibody","volume":"5","author":"Dao","year":"2013","journal-title":"Sci Transl Med"},{"key":"2025100300525009000_9.8.e002752.46","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.1158\/1078-0432.CCR-13-2756","article-title":"Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein","volume":"20","author":"Veomett","year":"2014","journal-title":"Clin Cancer Res"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-002752","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T07:53:05Z","timestamp":1759477985000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-002752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":46,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8,25]]},"published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1136\/jitc-2021-002752"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-002752","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8]]}}}